Business Context and Reporting Period
This Form 8-K is filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) for the reporting period ending November 30, 2011. The company is incorporated in Nevada and is headquartered in Englewood Cliffs, NJ. The filing reports on unregistered sales of equity securities and related financial instruments.
Key Financial Metrics and Transactions
The filing details specific equity issuances rather than standard financial performance metrics like revenue or cash flow.
- Direct Stock Issuance: 500,000 shares of common stock issued via a Subscription Agreement.
- Debt Conversion: 1,018,456 shares of common stock issued upon conversion of a convertible promissory note (principal and accrued interest) originally issued on September 22, 2011.
- Warrant Issuance: A warrant to purchase 250,000 shares at an exercise price of $1.00 per share was issued to the note holder.
- Total Shares Issued: 1,518,456 shares of common stock were issued on November 30, 2011.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, total debt, or liquidity positions.
Material Changes
The primary material change is the increase in outstanding common stock due to the direct issuance and the conversion of debt. The conversion of the September 2011 promissory note eliminated that specific debt obligation in exchange for equity.
Guidance, Risks, and Unusual Items
Regulatory Exemption: All securities were issued to an accredited investor in reliance on the exemption from registration under Section 4(2) of the Securities Act of 1933 and Rule 506.
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding future operations or financial performance.
Risks: The filing does not explicitly list new risk factors, though the issuance of significant equity may result in shareholder dilution.
Investor Verification Checklist
- Verify the exact terms of the Subscription Agreement (Exhibit 10.1) to confirm the purchase price per share for the 500,000 direct issuance.
- Confirm the total principal and accrued interest amount of the convertible note converted into 1,018,456 shares to assess the implied valuation.
- Review the September 27, 2011 Form 8-K referenced in the text for the original terms of the convertible note and warrant.
- Check subsequent filings for the updated total share count and potential dilution impact.